The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance Hike - Learn Why [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
This sharp step-up in expected sales comes after a year in which Insmed attracted attention for new respiratory drug approvals and pipeline setbacks alike. We'll now examine how Insmed's higher 2025 revenue guidance reshapes its investment narrative built around future respiratory therapy launches. Uncover the next big thing with financially sound penny stocks that balance risk and reward To own Insmed, you need to believe its focus on serious respiratory diseases can justify ongoing heavy investment and current losses. The new 2025 revenue guidance of US$606.4 million signals management's confidence in its commercial base, but it does not materially change the near term focus on brensocatib's U.S. approval timeline or the regulatory and payer risks that still sit in the foreground. The most closely linked recent announcement is the U.S. FDA's Priority Review for brensocatib in non cystic fibrosis bronchiectasis, with an August 12, 2025 action date and potential mid 2025 laun
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSMPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSMGlobeNewswire
- Insmed CEO Will Lewis talks its rare disease drug pipeline [CNBC]CNBC
- Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/12/26 - Form 144
- INSM's page on the SEC website